Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXVX0317 in prior alphavirus vaccine recipients
NCT03992872Phase 2Completed
- Sponsor
- Bavarian Nordic
- Start
- Nov 2019
- Primary completion
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of CHIKV VLP vaccine in Chikungunya (CHIKV) (2 arms), sponsored by Bavarian Nordic. Primary endpoint: Percentage of Participants With 4-fold Rise in Anti-CHIKV Neutralizing Antibody Response at Day 22. Started Nov 2019; status: completed.
02
Drugs
CHIKV VLP vaccine
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT03992872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992872.